Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients
Why the study?
Does baseline LVEF predict cardiovascular outcomes and mortality in patients with symptomatic heart failure?
Population
7599 patients with a broad spectrum of symptomatic heart failure enrolled in the CHARM Program.
Comparison
Candesartan at a target dose of 32 mg once daily vs Matching placebo
Design
Cohort, randomized, matching placebo
Follow-up
median of 38 months
Authors
Discussion
Loading...
Member takes
Implication
Supports LVEF-based risk stratification in symptomatic HF; leaves open whether EF-targeted interventions improve survival.
Structured PICO
Does baseline LVEF predict cardiovascular outcomes and mortality in patients with symptomatic heart failure?
P
Population
7599 patients with a broad spectrum of symptomatic heart failure enrolled in the CHARM Program.
I
Intervention
Candesartan at a target dose of 32 mg once daily
C
Comparator
Matching placebo
O
Outcome
All-cause mortality and cardiovascular outcomes (cardiovascular death, sudden death, heart failure-related death) in relation to baseline LVEFhard clinical
LVEF is a powerful predictor of cardiovascular outcomes in heart failure, with mortality risk increasing significantly as LVEF drops below 45%, but remaining relatively stable at higher ejection fractions.
Cite This Study
Solomon et al. (2005) studied this question.